Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia

27

Pipeline Programs↗

10

Active Trials↗

14

Companies Involved↗

B Acute Lymphoblastic Leukemia is an emerging landscape with 27 programs across 14 companies. 22 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

6/100

Mech. Concentration

22/100

Completion Rate

0/100

Attrition Rate

9/100

Pipeline

Programs by Phase

Preclinical

No programs

Phase 13

Fludarabine Phosphate

Sanofi

CD19CAR-CD28-Cd3zeta-Egfrt-Expressing Tcm-Enriched T-Lymphocytes

City of Hope Medical Center

Fludarabine

Sanofi

Phase 22

Methylprednisolone

Pfizer

Vincristine

Eli Lilly

Phase 322

Calaspargase Pegol

Servier

Cyclophosphamide

Baxter Healthcare Corporation

Cytarabine

Teva

Daunorubicin Hydrochloride

Eastern Cooperative Oncology Group

Dexamethasone

Aspen Global Incorporated

Approved

No programs

Analysis

Modality Breakdown

72%

Small molecule

18 of 25 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 25 classified programs, each share of the total. Modality classified for 96% of 27 pipeline programs.

Analysis

Trial Status

11

clinical trials

Active, not recruiting6 · 55%

Recruiting4 · 36%

Withdrawn1 · 9%

Clinical Trials

Trial Activity

11 trials

An International Phase 2 Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-Class Philadelphia Chromosome-Like B-Cell Acute Lymphoblastic Leukemia

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT06124157·222 enrolled

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL

Recruiting·Alliance for Clinical Trials in Oncology·Phase 3·NCT03150693·303 enrolled

Chronic Health Conditions in Down Syndrome-Associated Acute Leukemia: The Down Syndrome Phenotyping Acute Leukemia Study in Survivors (DS-PALS Survivors)

Recruiting·Children's Oncology Group·N/A·NCT05702645·330 enrolled

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Recruiting·Children's Oncology Group·Phase 3·NCT03959085·5,951 enrolled

A Pilot Study of CD19-Specific Car T Cells as Consolidation for Older Adults With Acute Lymphoblastic Leukemia in First Remission

Active, not recruiting·CCity of Hope Medical Center·Phase 1·NCT05707273·18 enrolled

A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy

Active, not recruiting·Children's Oncology Group·Phase 3·NCT05602194·440 enrolled

Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients With High-Risk CD19+ Acute Lymphoblastic Leukemia

Active, not recruiting·CCity of Hope Medical Center·Phase 1·NCT02146924·71 enrolled

A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)

Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT03914625·6,720 enrolled

A Randomized Phase II Study Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Plus Blinatumomab Compared to Usual Chemotherapy Plus Blinatumomab for Older Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma

Active, not recruiting·Alliance for Clinical Trials in Oncology·Phase 2·NCT05303792·68 enrolled

Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Active, not recruiting·SStanford University·Phase 1·NCT03241940·33 enrolled

Pilot Study of Pre-emptive Anakinra for the Prevention of Severe Cytokine Release Syndrome in Children and Young Adults With B-Acute Lymphoblastic Leukemia Receiving Chimeric Antigen Receptor (CAR) T Cells

Withdrawn·—·Preclinical·NCT06703216

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)